Delivery Order SPE2DB24D1201-SPE2DB25FJEAF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside contract with a completion date of August 15, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The order represents a child delivery order under a larger contract vehicle, enabling the pharmaceutical distributor to supply critical medical...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $28,029.17 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $24,402.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The award was made...
- The Defense Logistics Agency awarded a $14,455.29 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors with a ceiling value of $16,361.85. This firm fixed-price contract, which expires August 21, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procedures with no set-aside designation, and performance...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEAFDelivery Order
The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor agreement valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, has demonstrated consistent capability in fulfilling DLA medical supply requirements through competitively awarded contracts. The company's extensive portfolio includes brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Zepbound—a GLP-1 receptor agonist medication—aligns with the company's established track record supplying diabetes and endocrinology medications to military and veteran healthcare systems under its comprehensive DLA contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.4k | 8/28/25 |